Microbot Medical

Company Overview

Snapshot

Founded in November 2010 by Harel Gadot, Microbot Medical operates with 11–50 employees. The company has raised a total of $90.52 million across 15 funding rounds and went public on NASDAQ in November 2016. In September 2025, the company received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System.

Business overview

Microbot Medical specializes in transformational robotic technologies, primarily focusing on the endovascular space. Its core product, the LIBERTY Robotic System, is designed as the world’s first single-use endovascular robotic system, aiming to increase access to robotic technology and revolutionize endovascular procedures. The company serves the medical devices market, operating within the Health Tech & Life Sciences sector, with a focus on medical treatment and therapeutics.

Strategic signal

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System. This regulatory approval is a significant validation of the company's technology and signals a major step towards commercialization, indicating strong forward momentum for its robotic surgical solutions in the medical device market.

Company Intelligence Q&A

What was a significant recent regulatory milestone for Microbot Medical?

In September 2025, Microbot Medical received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, a key regulatory approval for its robotic surgical technology.

What was the outcome of Microbot Medical's pivotal human clinical trial for the LIBERTY system?

In October 2024, Microbot Medical announced the successful completion of its pivotal human clinical trial for the LIBERTY Endovascular Robotic Surgical System, accelerating its go-to-market strategy for a commercial launch in Q2 2025.

What was a recent financing activity for Microbot Medical?

In October 2025, Microbot Medical announced the final closing of the exercise of outstanding preferred investment options, raising up to $92.2 million in gross proceeds.

What was a recent strategic partnership for Microbot Medical?

In October 2025, Microbot Medical secured a U.S.-based logistics partner to support the commercialization of its LIBERTY Endovascular Robotic System, strengthening its market entry strategy.

When did Microbot Medical go public?

Microbot Medical initiated trading on NASDAQ as 'MBOT' in November 2016, following the completion of its merger transaction.